5-alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure - Activity relationship profile

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4641-4652

  Nawrozkij, Maxim B ^a   Rotili, Dante ^b   Tarantino, Domenico ^b   Botta, Giorgia ^b,e   Eremiychuk, Alexandre S ^a   Musmuca, Ira ^b   Ragno, Rino ^b   Samuele, Alberta ^c   Zanoli, Samantha ^c   Armand Ugón, Mercedes ^d   Clotet Codina, Imma ^d   Novakov, Ivan A ^a   Orlinson, Boris S ^a   Maga, Giovanni ^c   Esté, José A ^d   Artico, Marino ^b   Mai, Antonello ^b  

^a VOLGOGRAD STATE TECHNICAL UNIVERSITY   (Russian Federation)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDINE DERIVATIVE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; VIRUS MUTANT;

ALKYLATION; ANTI-HIV AGENTS; BENZENE; CHEMISTRY, PHYSICAL; ENZYME INHIBITORS; HIV-1; HYDROGEN; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; OXYGEN; PROTEIN BINDING; PYRIMIDINONES; RNA-DIRECTED DNA POLYMERASE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFUR COMPOUNDS;

EID: 49449113636     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800340w     Document Type: Article

References (59)

1. Artico, M. Selected non-nucleoside reverse transcriptase inhibitors (NNRTIs): the DABOs family. Drug Future 2002, 27, 159-175.
2. Marongiu, M. E.; Pani, A.; Musiu, C.; La Colla, P.; Mai, A.; Sbardella, G.; Massa, S.; Artico, M. 3,4-Dihydro-2-alkoxy-6-benzyl-oxopyrimidines (DABOs): Development of a potent class of non-nucleoside reverse transcriptase inhibitors. Recent Res. Dev. Med. Chem. 2001, 1, 65-92.
3. De Clercq, E. Emerging anti-HIV drugs. Expert Opin. Emerging Drugs 2005, 10, 241-273.
4. De Clercq, E. New Approaches toward Anti-HIV Chemotherapy. J. Med. Chem. 2005, 48, 1297-1313.
5. Campiani, G.; Ramunno, A.; Maga, G.; Nacci, V.; Fattorusso, C.; Catanalotti, E.; Morelli, E.; Novellino, E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr. Pharm. Des. 2002, 8, 615-657.
6. Botta, M.; Artico, M.; Massa, S.; Gambacorta, A.; Marongiu, M. E.; Pani, A.; La Colla, P. Synthesis, Antimicrobial and Antiviral Activities of Isotrimethoprim and Some Related Derivatives. Eur. J. Med. Chem. 1992, 27, 251-257.
7. Artico, M.; Massa, S.; Mai, A.; Marongiu, M. E.; Piras, G.; Tramontano, E.; La Colla, P. 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a New Class of Specific Inhibitors of Human Immunodeficiency Virus Type 1. Antiviral Chem. Chemother. 1993, 4, 361-368.
8. Tramontano, E.; Marongiu, M. E.; De Montis, A.; Loi, A. G.; Artico, M.; Massa, S.; Mai, A.; La Colla, P. Characterization of the Anti-HIV-1 Activity of 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), New Non-Nucleoside Reverse Transcriptase Inhibitors. Microbiologica 1994, 17, 269-279.
9. Massa, S.; Mai, A.; Artico, M.; Sbardella, G.; Tramontano, E.; Loi, A. G.; Scano, P.; La Colla, P. Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus Type-1. Antiviral Chem. Chemother. 1995, 6, 1-8.
10. Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Loi, A. G.; Tramontano, E.; Scano, P.; La Colla, P. Synthesis and anti-HIV-1 Activity of Thio Analogues of Dihydroalkoxybenzyloxopyrimidines. J. Med. Chem. 1995, 38, 3258-3263.
11. Ettorre, A.; Mai, A.; Artico, M.; Massa, S.; De Montis, A.; La Colla, P. 6-(3-Methylbenzyl)-2-(2-methylpropyl)thio-4(3H)-pyrimidinone (DABO 622). Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1996, 52, 2115-2117.
12. Mai, A.; Artico, M.; Sbardella, G.; Quartarone, S.; Massa, S.; Loi, A. G.; De Montis, A.; Scintu, F.; Putzolu, M.; La Colla, P. Dihydro(alkylthio) (naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series. J. Med. Chem. 1997, 40, 1447-1454.
13. Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Novellino, E.; Greco, G.; Loi, A. G.; Tramontano, E.; Marongiu, M. E.; La Colla, P. 5-Alkyl-2-(alkylthio)- 6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones: Novel Potent and Selective Dihydro-alkoxy-benzyl-oxopyrimidine Derivatives. J. Med. Chem. 1999, 42, 619-627.
14. Sbardella, G.; Mai, A.; Artico, M.; Massa, S.; Marceddu, T.; Vargiu, L.; Marongiu, M. E.; La Colla, P. Does the 2-Methylthiomethyl Substituent Really Confer High Anti-HIV-1 Activity to S-DABOs. Med. Chem. Res. 2000, 10, 30-39.
15. Sbardella, G.; Mai, A.; Artico, M.; Chimenti, P.; Massa, S.; Loddo, R.; Marongiu, M. E.; La Colla, P.; Pani, A. Structure-activity relationship studies on new DABOs: effect of substitutions at pyrimidine C-5 and C-6 positions on anti-HIV-1 activity. Antiviral Chem. Chemother. 2001, 12, 37-50.
16. Pani, A.; Musiu, C.; Loi, A. G.; Mai, A.; Loddo, R.; La Colla, P.; Marongiu, M. E. DABOs as candidates to prevent mucosal HIV transmission. Antiviral Chem. Chemother. 2001, 12, 51-59.
17. Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Novellino, E.; Greco, G.; Lavecchia, A.; Musiu, C.; La Colla, M.; Murgioni, C.; La Colla, P.; Loddo, R. Structure-based Design, Synthesis, and Biological Evaluation of Conformationally Restricted Novel 2-Alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3, 4-dihydro-5-alkylpyrimidin-4(3H)-ones as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. J. Med. Chem. 2001, 44, 2544-2554.
18. Quaglia, M. G.; Mai, A.; Sbardella, G.; Artico, M.; Ragno, R.; Massa, S.; Del Piano, D.; Setzu, G.; Doratiotto, S.; Cotichini, V. Chiral Resolution and Molecular Modeling Investigation of rac-2-Cyclopentylthio-6-[1-(2,6- difluorophenyl)ethyl]-3,4-dihydro-5-methylpyrimidin-4(3H)-one (MC-1047), a Potent Anti-HIV-1 Reverse Transcriptase Agent of the DABO Class. Chirality 2001, 13, 75-80.
19. Ragno, R.; Mai, A.; Sbardella, S.; Artico, M.; Massa, S.; Musiu, C.; Mura, M.; Marceddu, T.; Cadeddu, A.; La Colla, P. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6- difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J. Med. Chem. 2004, 47, 928-934.
20. Mai, A.; Artico, M.; Ragno, R.; Sbardella, G.; Massa, S.; Musiu, C.; Mura, M.; Marturana, F.; Cadeddu, A.; Maga, G.; La Colla, P. 5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3 H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. Bioorg. Med. Chem. 2005, 13, 2065-2077.
21. Cancio, R.; Mai, A.; Rotili, D.; Artico, M.; Sbardella, G.; Clotet-Codina, I.; Esté, J. A.; Crespan, E.; Zanoli, S.; Hübscher, U.; Spadari, S.; Maga, G. Slow-, Tight-Binding HIV-1 Reverse Transcriptase Non-Nucleoside Inhibitors Highly Active against Drug-Resistant Mutants. ChemMedChem 2007, 2, 445-448.
22. Mai, A.; Artico, M.; Rotili, D.; Tarantino, D.; Clotet-Codina, I.; Armand-Ugón, M.; Ragno, R.; Simeoni, S.; Sbardella, G.; Nawrozkij, M. B.; Samuele, A.; Maga, G.; Esté, J. A. Synthesis and Biological Properties of Novel 2-Aminopyrimidin-4(3H)-ones Highly Potent Against HIV-1 Mutant Strains. J. Med. Chem. 2007, 50, 5412-5424.
23. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C.-F.; Walker, R. T.; Miyasaka, T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165, 1375-1381.
24. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R. T.; Balzarini, J.; De Clercq, E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 1989, 32, 2507-2509.
25. Yuasa, S.; Sadakata, Y.; Takashima, H.; Sekiya, K.; Inouye, N.; Ubasawa, M.; Baba, M. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol. Pharmacol. 1993, 44, 895-900.
26. Baba, M.; Shigeta, S.; Yuasa, S.; Takashima, H.; Sekiya, K.; Ubasawa, M.; Tanaka, H.; Miyasaka, T.; Walker, R. T.; De Clercq, E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 1994, 38, 688-692.
27. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Inouye, N.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio) thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 1995, 38, 2860-2865.
28. Hopkins, A. L.; Ren, J.; Tanaka, H.; Baba, M.; Okamato, M.; Stuart, D. I.; Stammers, D. K. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J. Med. Chem. 1999, 42, 4500-4505.
29. 13 The physical and chemical data for compounds 1a-p have been reported in Table S1 as Supporting Information. Compounds 1q,r, here reported for a direct comparison as reference drugs, were described in ref 13.
30. Mugnaini, C.; Manetti, F.; Esté, J. A.; Clotet-Codina, I.; Maga, G.; Cancio, R.; Botta, M.; Corelli, F. Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 3541-3544.
31. Manetti, F.; Esté, J. A.; Clotet-Codina, I.; Armand-Ugòn, M.; Maga, G.; Crespan, E.; Cancio, R.; Mugnaini, C.; Bernardini, C.; Togninelli, A.; Carmi, C.; Alongi, M.; Petricci, E.; Massa, S.; Corelli, F.; Botta, M. Parallel Solution-Phase and Microwave-Assisted Synthesis of New S-DABO Derivatives Endowed with Subnanomolar Anti-HIV-1 Activity. J. Med. Chem. 2005, 48, 8000-8008.
32. Mugnaini, C.; Alongi, M.; Togninelli, A.; Gevarija, H.; Brizzi, A.; Manetti, F.; Bernardini, C.; Angeli, L.; Tafi, A.; Bellucci, L.; Corelli, F.; Massa, S.; Maga, G.; Samuele, A.; Facchini, M.; Clotet-Codina, I.; Armand-Ugón, M.; Esté, J. A.; Botta, M. Dihydro-alkylthio-benzyl- oxopyrimidines as Inhibitors of Reverse Transcriptase: Synthesis and Rationalization of the Biological Data on Both Wild-Type Enzyme and Relevant Clinical Mutants. J. Med. Chem. 2007, 50, 6580-6505.
33. He, Y.; Chen, F.; Sun, G.; Wang, Y.; De Clercq, E.; Balzarini, J.; Pannecouque, C. 5-Alkyl-2-[(aryl and lakyloxylcarbonylmethyl)thio]-6-(1- naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. Bioorg. Med. Chem. Lett. 2004, 14, 3173-3176.
34. He, Y.; Chen, F.; Yu, X.; Wang, Y.; De Clercq, E.; Balzarini, J.; Pannecouque, C. Non-nucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones. Bioorg. Chem. 2004, 32, 536-548.
35. Brown, H. C.; Rogic, M. M.; Rathke, M. W.; Kabalka, G. W. Mono-and dialkylation of ethyl dihaloacetates by reaction with organoboranes under the influence of potassium tert-butoxide. Convenient procedures for the conversion of olefins into the alpha-halo alkanoic or dialkylacetic acid esters via hydroboration. J. Am. Chem. Soc. 1968, 90, 1911-1913.
36. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
37. Deshpande, N.; Addess, K. J.; Bluhm, W. F.; Merino-Ott, J. C.; Townsend-Merino, W.; Zhang, Q.; Knezevich, C.; Xie, L.; Chen, L.; Feng, Z.; Green, R. K.; Flippen-Anderson, J. L.; Westbrook, J.; Berman, H. M.; Bourne, P. E. The RCSB Protein Data Bank: a redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res. 2005, 33, D233-D237.
38. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D. I.; Stammers, D. K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 2001, 312, 795-805.
39. Ren, J.; Nichols, C. E.; Chamberlain, P. P.; Weaver, K. L.; Short, S. A.; Stammers, D. K. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106, and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol. 2004, 336, 569-578.
40. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
41. Esnouf, R. M.; Ren, J.; Hopkins, A. L.; Ross, C. K.; Jones, E. Y.; Stammers, D. K.; Stuart, D. I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this non-nucleoside inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 3984-3989.
42. Armand-Ugon, M.; Gutierrez, A.; Clotet, B.; Esté, J. A. HIV-1 Resistance to the gp41-Dependent Fusion Inhibitor C-34. Antiviral Res. 2003, 59, 137-142.
43. Moncunill, G.; Armand-Ugon, M.; Clotet, I.; Pauls, E.; Ballana, E.; Llano, A.; Romagnoli, B.; Vrijbloed, J. W.; Gombert, F. O.; Clotet, B.; De Marco, S.; Esté, J. A. Anti-HIV Activity and Resistance Profile of the CXCR4 Antagonist POL3026. Mol. Pharmacol. 2008, 73, 1264-1273.
44. Moncunill, G.; Armand-Ugon, M.; Pauls, E.; Clotet, B.; Esté, J. A. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008, 22, 23-31.
45. Maga, G.; Amacker, M.; Ruel, N.; Hubscher, U.; Spadari, S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 1997, 274, 738-747.
46. Westbrook, J.; Feng, Z.; Chen, L.; Yang, H.; Berman, H. M. The Protein Data Bank and structural genomics. Nucleic Acids Res. 2003, 31, 489-491.
47. Berman, H.; Henrick, K.; Nakamura, H. Announcing the Worldwide Protein Data Bank. Nat. Struct. Biol. 2003, 10, 980.
48. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
49. Martin A. C. R. Profit 2.2; http://www.bioinf.org.uk/software/ profit/.
50. McLachlan, A. D. Rapid comparison of protein structures. Acta Crystallogr., Sect. A: Found. Crystallogr. 1982, 38, 871-873.
51. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera: A Visualization System for Exploratory Research and Analysis. J. Comput. Chem. 2004, 25, 1605-1612.
52. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. AMBER 8; University of California: San Francisco., 2004.
53. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; William, E.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
54. Sousa, S. F.; Fernandes, P. A.; Ramos, M. J. Protein-ligand docking: current status and future challenges. Proteins 2006, 65, 15-26.
55. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 2007, 28, 1145-1152.
56. Ragno, R.; Frasca, S.; Manetti, F.; Brizzi, A.; Massa, S. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. J. Med. Chem. 2005, 48, 200-212.
57. Krause, S.; Willighagen, E.; Steinbeck, C. J. ChemPaint: Using the Collaborative Forces of the Internet to Develop a Free Editor for 2D Chemical Structures. Molecules 2000, 5, 93-98.
58. Steinbeck, C.; Hoppe, C.; Kuhn, S.; Floris, M.; Guha, R.; Willighagen, E. L. Recent developments of the chemistry development kit (CDK): an open-source Java library for chemo- and bioinformatics. Curr. Pharm. Des. 2006, 12, 2111-2120.
59. Steinbeck, C.; Han, Y.; Kuhn, S.; Horlacher, O.; Luttmann, E.; Willighagen, E. The Chemistry Development Kit (CDK): an open-source Java library for Chemo- and Bioinformatics. J. Chem. Inf. Comput. Sci. 2003, 43, 493-500.